Recap: Oncology Institute Q4 Earnings
Portfolio Pulse from Benzinga Insights
Oncology Institute (NASDAQ:TOI) reported Q4 earnings with a significant miss on estimated earnings by -91.0%, posting an EPS of $-0.21 against an estimate of $-0.11. Despite this, revenue increased by $14.36 million from the same period last year. In the previous quarter, despite missing EPS estimates, the share price increased by 28% the following day.
March 27, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oncology Institute reported a significant miss in Q4 earnings with an EPS of $-0.21, far below the estimated $-0.11, but showed an increase in revenue by $14.36 million from the previous year.
Although TOI missed the estimated earnings significantly, the increase in revenue and historical context of stock price increase following a miss in the previous quarter suggest a neutral short-term impact. Investors might weigh the revenue growth against the earnings miss, leading to uncertain price movement.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100